Pharsight

Drugs that contain Diclofenac Potassium

1. Cambia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8097651 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

US7759394 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6974595 ASSERTIO Pharmaceutical compositions based on Diclofenae
May, 2017

(7 years ago)

US7482377 ASSERTIO Pharmaceutical compositions and methods of treatment based on diclofenac
May, 2017

(7 years ago)

US9827197 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

US8927604 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 17, 2012

Market Authorisation Date: 17 June, 2009

Treatment: Acute treatment of migraine attacks with or without aura in adults

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of CAMBIA before it's drug patent expiration?
More Information on Dosage

CAMBIA family patents

Family Patents

2. Zipsor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6287594 ASSERTIO Oral liquid compositions
Jan, 2019

(5 years ago)

US6365180 ASSERTIO Oral liquid compositions
Jul, 2019

(4 years ago)

US7939518 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(4 years from now)

US8623920 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(4 years from now)

US9561200 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(4 years from now)

US8110606 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(4 years from now)

US7884095 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(4 years from now)

US7662858 ASSERTIO Method of treating post-surgical acute pain
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 25, 2024
New Dosage Form(NDF) Jun 16, 2012

Market Authorisation Date: 16 June, 2009

Treatment: Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain; Diclofenac potassium for relief of mild to moderate acute pain

Dosage: CAPSULE;ORAL

How can I launch a generic of ZIPSOR before it's drug patent expiration?
More Information on Dosage

ZIPSOR family patents

Family Patents